

Eurofins enhances clinical and biopharma services in Japan

May 31, 2022 | News

Eurofins has acquired Osaka based Repertoire Genesis



Eurofins Scientific, a global scientific leader in bioanalytical testing and clinical diagnostics testing, has announced the completion of the acquisition of a majority stake in Repertoire Genesis Inc. (RG).

RG owns a unique and proprietary analytical platform, TCR/BCR (T Cell Receptor/B Cell Receptor) repertoire profiling, that enables scientists to determine the specific pathophysiological status of immune responses derived from cancer, autoimmune diseases, transplants, and infectious diseases.

RG's analytical platform is an important resource for immune-related translational research, biomarker, diagnostics and pharmaceutical development from discovery stage through to clinical trials. The acquisition of RG will further expand Eurofins' service offering to the healthcare sector globally and strengthen its unique service portfolio and position in the global bioanalytical market.

RG, with over 20 staff based in its laboratory in Osaka, is leading innovation in repertoire analysis, and is expected to establish a leading position in the Japanese bioanalytical market as a solution provider for immune-related diseases and research. Since its establishment in 2014, RG has developed and offered long-read TCR/BCR repertoire analysis based on novel bioinformatics through a wide range of R&D activity from translational research to clinical trials. RG has a master patent granted in Japan, the United States, and Europe and was the first laboratory accredited against ISO/IEC 17025 in the field of TCR/BCR repertoire analysis.